BACKGROUND: Inflammatory cytokines, including tumor necrosis factor alpha, IL-6 (interleukin 6), and high-sensitivity C-reactive protein (hsCRP), have been related to both insulin resistance and type 2 diabetes mellitus. However, prospective studies that comprehensively assess their roles in the development of type 2 diabetes are few, especially in minority populations. METHODS: Among 82,069 postmenopausal women aged 50 to 79 years without cardiovascular disease or diabetes mellitus who participated in the Women's Health Initiative Observational Study, we prospectively examined the relationships of plasma levels of tumor necrosis factor alpha receptor 2, IL-6, and hsCRP to diabetes risk. During a median follow-up period of 5.9 years, 1584 women who had clinical diabetes were matched by age, ethnicity, clinical center, time of blood draw, and duration of follow-up to 2198 study participants who were free of the disease. RESULTS: After adjustment for matching factors and known diabetes risk factors, all 3 markers were significantly associated with increased diabetes risk; the estimated relative risks comparing the highest with the lowest quartiles were 1.47 (95% confidence interval [CI], 1.10-1.97) for tumor necrosis factor alpha receptor 2, 3.08 (95% CI, 2.25-4.23) for IL-6, and 3.46 (95% CI, 2.50-4.80) for hsCRP (P for trend, <.01 for all biomarkers). When mutually adjusted, IL-6 and hsCRP remained significant in each ethnic group. While no statistically significant interactions were observed between ethnicity and these biomarkers on diabetes risk, there were consistent trends for the associations of hsCRP and IL-6 with increased diabetes risk in all ethnic groups. CONCLUSION: These prospective data showed that elevated levels of IL-6 and hsCRP were consistently and significantly associated with an increased risk of clinical diabetes in postmenopausal women.
BACKGROUND: Inflammatory cytokines, including tumor necrosis factor alpha, IL-6 (interleukin 6), and high-sensitivity C-reactive protein (hsCRP), have been related to both insulin resistance and type 2 diabetes mellitus. However, prospective studies that comprehensively assess their roles in the development of type 2 diabetes are few, especially in minority populations. METHODS: Among 82,069 postmenopausal women aged 50 to 79 years without cardiovascular disease or diabetes mellitus who participated in the Women's Health Initiative Observational Study, we prospectively examined the relationships of plasma levels of tumor necrosis factor alpha receptor 2, IL-6, and hsCRP to diabetes risk. During a median follow-up period of 5.9 years, 1584 women who had clinical diabetes were matched by age, ethnicity, clinical center, time of blood draw, and duration of follow-up to 2198 study participants who were free of the disease. RESULTS: After adjustment for matching factors and known diabetes risk factors, all 3 markers were significantly associated with increased diabetes risk; the estimated relative risks comparing the highest with the lowest quartiles were 1.47 (95% confidence interval [CI], 1.10-1.97) for tumor necrosis factor alpha receptor 2, 3.08 (95% CI, 2.25-4.23) for IL-6, and 3.46 (95% CI, 2.50-4.80) for hsCRP (P for trend, <.01 for all biomarkers). When mutually adjusted, IL-6 and hsCRP remained significant in each ethnic group. While no statistically significant interactions were observed between ethnicity and these biomarkers on diabetes risk, there were consistent trends for the associations of hsCRP and IL-6 with increased diabetes risk in all ethnic groups. CONCLUSION: These prospective data showed that elevated levels of IL-6 and hsCRP were consistently and significantly associated with an increased risk of clinical diabetes in postmenopausal women.
Authors: Mariana C Calle; Sonia Vega-López; Sofia Segura-Pérez; Jeff S Volek; Rafael Pérez-Escamilla; Maria Luz Fernandez Journal: J Diabetes Metab Date: 2010-11-10
Authors: Yian Gu; Roy E Shore; Alan A Arslan; Karen L Koenig; Mengling Liu; Sherif Ibrahim; Anna E Lokshin; Anne Zeleniuch-Jacquotte Journal: Cancer Causes Control Date: 2010-04-07 Impact factor: 2.506
Authors: Chun Chao; Yiqing Song; Nancy Cook; Chi-Hong Tseng; JoAnn E Manson; Charles Eaton; Karen L Margolis; Beatriz Rodriguez; Lawrence S Phillips; Lesley F Tinker; Simin Liu Journal: Arch Intern Med Date: 2010-09-27
Authors: Jung Ho Gong; Kenneth Lo; Qing Liu; Jie Li; Shuiqing Lai; Aladdin H Shadyab; Chrisa Arcan; Linda Snetselaar; Simin Liu Journal: Diabetes Care Date: 2020-04-15 Impact factor: 19.112
Authors: Yunsheng Ma; James R Hébert; Wenjun Li; Elizabeth R Bertone-Johnson; Barbara Olendzki; Sherry L Pagoto; Lesley Tinker; Milagros C Rosal; Ira S Ockene; Judith K Ockene; Jennifer A Griffith; Simin Liu Journal: Nutrition Date: 2008-06-18 Impact factor: 4.008
Authors: Brian H Chen; Kathleen Brennan; Atsushi Goto; Yiqing Song; Najib Aziz; Nai-chieh Y You; Melissa F Wellons; JoAnn E Manson; Donna L White; Anthony W Butch; Simin Liu Journal: Clin Chem Date: 2012-08-20 Impact factor: 8.327